- Home
- CDTG vs OVID Comparison
CDTG vs OVID Comparison
Compare CDTG & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- OVID
- Stock Information
- Founded
- CDTG 2012
- OVID 2014
- Country
- CDTG China
- OVID United States
- Employees
- CDTG N/A
- OVID N/A
- Industry
- CDTG
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- OVID Health Care
- Exchange
- CDTG NYSE
- OVID Nasdaq
- Market Cap
- CDTG 24.5M
- OVID 20.6M
- IPO Year
- CDTG 2024
- OVID 2017
- Fundamental
- Price
- CDTG $0.84
- OVID $0.31
- Analyst Decision
- CDTG
- OVID Strong Buy
- Analyst Count
- CDTG 0
- OVID 4
- Target Price
- CDTG N/A
- OVID $3.13
- AVG Volume (30 Days)
- CDTG 723.4K
- OVID 969.8K
- Earning Date
- CDTG 05-15-2025
- OVID 08-12-2025
- Dividend Yield
- CDTG N/A
- OVID N/A
- EPS Growth
- CDTG N/A
- OVID N/A
- EPS
- CDTG 0.14
- OVID N/A
- Revenue
- CDTG $29,765,205.00
- OVID $548,000.00
- Revenue This Year
- CDTG N/A
- OVID N/A
- Revenue Next Year
- CDTG N/A
- OVID $5.32
- P/E Ratio
- CDTG $5.97
- OVID N/A
- Revenue Growth
- CDTG N/A
- OVID 15.61
- 52 Week Low
- CDTG $0.52
- OVID $0.24
- 52 Week High
- CDTG $4.64
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- OVID 52.32
- Support Level
- CDTG N/A
- OVID $0.29
- Resistance Level
- CDTG N/A
- OVID $0.32
- Average True Range (ATR)
- CDTG 0.00
- OVID 0.03
- MACD
- CDTG 0.00
- OVID 0.00
- Stochastic Oscillator
- CDTG 0.00
- OVID 50.50
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.